A Cohort of antithrombotic use and Optimal INR Level in patients with non-valvular atrial fibrillation in Thailand.
Phase 4
Recruiting
- Conditions
- Patients with non-valvular atrial fibrillationatrial fibrillation,anticoagulant,warfarin,time in therapeutic range
- Registration Number
- TCTR20160113002
- Lead Sponsor
- Health systems research institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 4000
Inclusion Criteria
Patient age > 18 years
Atrial fibrillation recorded from 12-lead ECG, ambulatory monitoring, intracardiac recordings
Exclusion Criteria
Ischemic stroke within 3 months before enrolment
Bleeding disorders
Prosthetic heart valve or valve repair
significant valvular disease
Participating in other blinded clinical trials
Severe comorbidities
Pregnancy
Unable to follow up
Not willing to sign informed consent
Hospitalisation within 1 month
Initiation of warfarin within 1 month
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Optimal INR level 3 years Incidence density
- Secondary Outcome Measures
Name Time Method Prevalence and pattern of antithrombotic therapy in patients with atrial fibrillation Cross-sectional Descriptive,Risk of stroke and systemic embolism according to CHADS2 and CHA2DS2VASc score 3 year Descriptive,Risk of bleeding with OAC treatment according to HASBLED and other bleeding risk scores 3 years Descriptive,Time-in-therapeutic range of atrial fibrillation patients who are taking warfarin in Thailand 3 years Rosendaal method,Prevalence of dementia in patients with atrial fibrillation 3 years Screening questionnaire,Prevalence of obstructive sleep apnea in patients with atrial fibrillation 3 years Screening questionnaire